NBIX:NGS-Neurocrine Biosciences Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 127.01

Change

-0.16 (-0.13)%

Market Cap

USD 4.26B

Volume

0.89M

Analyst Target

USD 140.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.07 (+0.54%)

USD 13.87B
ITCI Intracellular Th

-0.27 (-0.31%)

USD 9.17B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing NBIX

IBRN iShares Trust - iShares N.. 3.61 % 0.00 %

-0.35 (-1.26%)

USD 4.01M
FBT:LSE First Trust Global Funds .. 3.52 % 0.00 %

+5.20 (+-1.26%)

USD 8.45M
FBTU:LSE First Trust Global Funds .. 3.52 % 0.00 %

-0.06 (-1.26%)

USD 8.45M
LABU Direxion Daily S&P Biotec.. 1.47 % 1.14 %

-2.08 (-1.26%)

USD 0.99B
LABS 0.00 % 0.45 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

-0.64 (-1.26%)

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.21 (+-1.26%)

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

-0.73 (-1.26%)

USD 0.38B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

-0.61 (-1.26%)

USD 0.23B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-1.13 (-1.26%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.02 (-1.26%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.61% 56% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.61% 56% F 40% F
Trailing 12 Months  
Capital Gain 13.02% 58% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.02% 58% F 53% F
Trailing 5 Years  
Capital Gain 15.60% 70% C- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.60% 67% D+ 50% F
Average Annual (5 Year Horizon)  
Capital Gain 7.24% 51% F 58% F
Dividend Return 7.24% 51% F 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.11% 96% N/A 75% C
Risk Adjusted Return 34.31% 81% B- 66% D+
Market Capitalization 4.26B 99% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.59 52% 30%
Price/Book Ratio 4.48 34% 27%
Price / Cash Flow Ratio 31.73 10% 10%
Price/Free Cash Flow Ratio 20.14 17% 18%
Management Effectiveness  
Return on Equity 16.35% 90% 87%
Return on Invested Capital 7.88% 82% 73%
Return on Assets 11.80% 96% 96%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.